FemasysFEMY
FEMY
About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Employees: 34
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
43% more capital invested
Capital invested by funds: $1.8M [Q3] → $2.57M (+$769K) [Q4]
8% more funds holding
Funds holding: 26 [Q3] → 28 (+2) [Q4]
2.9% more ownership
Funds ownership: 7.31% [Q3] → 10.21% (+2.9%) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
757%
upside
Avg. target
$12
757%
upside
High target
$12
757%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 28 / 157 met price target | 757%upside $12 | Buy Reiterated | 13 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
21 hours ago
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control First-in-world approval of FemBloc delivery system for women seeking permanent birth control
Neutral
GlobeNewsWire
2 weeks ago
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the peer-reviewed publication of positive data from its initial clinical trials of FemBloc® permanent birth control in the Journal of Gynecology & Reproductive Medicine (JGRM) , a leading peer-reviewed journal covering gynecology and reproductive medicine.
Neutral
GlobeNewsWire
1 month ago
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products Regulatory Agency (MHRA) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection. “This is another key milestone as we expand our reach to the UK following successful approval across Europe for our innovative infertility and cancer detection products.
Neutral
GlobeNewsWire
1 month ago
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
Neutral
GlobeNewsWire
1 month ago
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
FemaSeed® patent application provides additional coverage for Femasys' therapeutic option for women seeking infertility solution
Neutral
GlobeNewsWire
3 months ago
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
Negative
Zacks Investment Research
4 months ago
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
Neutral
GlobeNewsWire
4 months ago
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control
Neutral
GlobeNewsWire
5 months ago
Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
Charts implemented using Lightweight Charts™